Clinical value of serum level of ryanodine receptor antibodies in diagnosis of myasthenia gravis
10.3760/cma.j.issn.1671-8925.2008.12.015
- VernacularTitle:重症肌无力患者血清Ryanodine受体抗体与临床的相关性研究
- Author:
Zhi-Hui YAN
1
;
Dong XU
;
Li-Quan DONG
;
Ling GAO
;
Ya-Bo FENG
;
Feng-Yan WANG
Author Information
1. 山东省烟台市烟台山医院
- Keywords:
Myasthenia gravis;
Rryanodine receptor-antibodies;
Thymoma
- From:
Chinese Journal of Neuromedicine
2008;7(12):1242-1244
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical value of detecting the serum level of ryanodine receptor antibodies (RyR-Ab) in the diagnosis and evaluation of myasthenia gravis (MG). Methods Enzyme-linked immunosorbent assay (ELISA) and Western blotting were used to detect the serum level of RyR-Ab in 81 patients with MG, 45 non-MG patients with other neurological disorders and 50 healthy control subjects. Results The results of ELISA showed a serum RyR-Ab positivity rate of 23.4% in the in MG patients, significantly higher than the rates in non-MG patients and the healthy subjects (P<0.05). The serum RyR-Ab positivity rate was 77.2% in MG patients with thymoma (MGT), 14.2% in those with thymie atrophy (MGA), and 6.6% in those with thymie hyperplasia (MGH). A positive correlation was found between the titer of serum RyR-Ab and the severity of muscle weakness (r=0.547, P<0.05). Compared with CT scanning, serum RyR-Ab level had low sensitivity (77.2%) but high specificity (91%, P<0.05) for diagnosis of MGT. According to the results of Western blotting, the serum RyR-Ab positivity rate was 81.8% in MGT patients, significantly higher than that in thymomβ-free MG patients and NMG patients (P<0.05). Conclusion RyR-Ab positivity is mainly found in MGT patients, and detection of serum RyR-Ab may help evaluate the severity of MG and assist in CT-based diagnosis of MGT.
